Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
Portfolio Pulse from
Regulus Therapeutics reported its Q3 2024 financial results, highlighting the completion of enrollment in the Phase 1b trial of RGLS8429 for ADPKD. The company is on track for an End-of-Phase 1 meeting by year-end and has a cash runway into H1 2026.
November 07, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regulus Therapeutics completed enrollment in the Phase 1b trial for RGLS8429, targeting ADPKD, and is preparing for an End-of-Phase 1 meeting. The company has a strong cash position, supporting operations into H1 2026.
The completion of enrollment in the Phase 1b trial is a significant milestone for Regulus, indicating progress in their clinical development. The upcoming End-of-Phase 1 meeting could provide further positive updates. The strong cash position ensures financial stability, supporting continued operations and development efforts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100